# HER-SAFE (NCT05880160)

> Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: recovered HER2-targeted therapy-related cardiac dysfunction

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05880160
- Phase: NA
- Status: COMPLETED
- Sponsor: University College, London
- Conditions: Cardiotoxicity; HER2-positive Breast Cancer; Heart Failure; Cancer, Therapy-Related
- Interventions: Phased withdrawal of heart failure medications
- Enrollment: 90
- Primary outcome: Relapse in Cardiotoxicity

## Indexed commentary on HER-SAFE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=her-safe-nct05880160